Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

by Steven E. Coutre, Ian W. Flinn, Sven de Vos, Jacqueline C. Barrientos, Marshall T. Schreeder, Nina D. Wagner-Johnson, Jeff P. Sharman, Thomas E. Boyd, Nathan Fowler, Lyndah Dreiling, Yeonhee Kim, Siddhartha Mitra, Kanti Rai, John P. Leonard, Richard R. Furman
Published 2018-06-01

Corrupted coordination of epigenetic modifications leads to diverging chromatin states and transcriptional heterogeneity in CLL

by Alessandro Pastore, Federico Gaiti, Sydney X. Lu, Ryan M. Brand, Scott Kulm, Ronan Chaligne, Hongcang Gu, Kevin Y. Huang, Elena K. Stamenova, Wendy Béguelin, Yanwen Jiang, Rafael C. Schulman, Kyu-Tae Kim, Alicia Alonso, John N. Allan, Richard R. Furman, Andreas Gnirke, Catherine J. Wu, Ari M. Melnick, Alexander Meissner, Bradley E. Bernstein, Omar Abdel-Wahab, Dan A. Landau
Published 2019-04-01

Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3′ Splice Site Selection through Use of a Different Branch Point

by Rachel B. Darman, Michael Seiler, Anant A. Agrawal, Kian H. Lim, Shouyong Peng, Daniel Aird, Suzanna L. Bailey, Erica B. Bhavsar, Betty Chan, Simona Colla, Laura Corson, Jacob Feala, Peter Fekkes, Kana Ichikawa, Gregg F. Keaney, Linda Lee, Pavan Kumar, Kaiko Kunii, Crystal MacKenzie, Mark Matijevic, Yoshiharu Mizui, Khin Myint, Eun Sun Park, Xiaoling Puyang, Anand Selvaraj, Michael P. Thomas, Jennifer Tsai, John Y. Wang, Markus Warmuth, Hui Yang, Ping Zhu, Guillermo Garcia-Manero, Richard R. Furman, Lihua Yu, Peter G. Smith, Silvia Buonamici
Published 2015-11-01